The biomedical industry grew at an accelerated pace in 2021 even as healthcare systems went into overdrive amidst the COVID-induced medical emergency.
Ocean Biomedical slashes IPO size. Should you invest in the stock?
Categories
Biotechnology
Regeneron Pharmaceuticals Inc. (REGN) Q4 2021 Earnings Call Transcript
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Q4 2021 earnings call dated Feb. 04, 2022 Corporate Participants: Mark Hudson -- Director, Investor Relations Leonard S. Schleifer -- Founder,
Infographic: A snapshot of Merck’s Q4 2021 earnings
Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than expected earnings and revenues for the fourth quarter. The positive outcome
BIIB Earnings: Key quarterly highlights from Biogen’s Q4 2021 financial results
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2021 earnings results today. Total revenue decreased 4% year-over-year to $2.73 billion. GAAP net income
Arcellx readies for $140-mln IPO. Here’s all you need to know
The IPO market is recovering from the slowdown experienced towards the end of 2021, with pharma companies dominating the scene in the
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2021 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q4 2021 earnings call dated Jan. 26, 2022 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations
INTERVIEW: Evelo’s SINTAX medicines could address a broad range of inflammatory disorders
Credit:DavidBGray on iStock Evelo Biosciences (Nasdaq:EVLO) is a clinical-stage biotechnology company that is focused on a newly uncovered area of central human
Bristol-Myers bets on product pipeline to beat patent issues. Is BMY a buy?
The pharma sector has been on a stable growth trajectory lately, and the trend gathered momentum when the pandemic-related emergency made companies
Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
Credit:DavidBGray on iStock Tell us a bit about your clinical programs and how they are different from the existing therapies. Addex is
Equillium CEO Bruce Steel: We are among the few evaluated in first-line GVHD treatment
Credit:DavidBGray on iStock What is Equillium all about? We started the company four years ago around our lead drug program itolizumab. My
Avid Bioservices, Inc. (CDMO) Q2 2022 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ: CDMO) Q2 2022 earnings call dated Dec. 07, 2021 Corporate Participants: Tim Brons -- Investor Relations, Vida Strategic Partners Nicholas
IPO Alert: Cancer drug company Nuvectis Pharma set for $30-million IPO
After months of hectic activity, the IPO market experienced a lull in the Thanksgiving week, but it is still headed for a
Biogen (BIIB) stock research summary | Q3 2021
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2021 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) Q4 2021 earnings call, dated Nov. 22, 2021. Corporate Participants: Vince Anzalone -- Vice President of Investor Relations Christopher
Cara Therapeutics, Inc. (CARA) Q3 2021 Earnings Call Transcript
Cara Therapeutics, Inc. (NASDAQ: CARA) Q3 2021 earnings call dated Nov. 08, 2021 Corporate Participants: Will Gramig -- Senior Analyst Derek Chalmers -- Chief Executive Officer,
Corcept Therapeutics Incorporated (CORT) Q3 2021 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q3 2021 earnings call dated Nov. 03, 2021 Corporate Participants: Atabak Mokari -- Chief Financial Officer Charles Robb -- Chief Business
Evelo Biosciences Inc (EVLO) Q3 2021 Earnings Call Transcript
Evelo Biosciences Inc (NASDAQ: EVLO) Q3 2021 earnings call dated Oct. 28, 2021 Corporate Participants: Kendra Sweeney -- Head of Investor Relations
Avalo Therapeutics CEO Mike Cola on product pipeline and market potential
Credit:DavidBGray on iStock What’s the significance of the name change and why now? Mike: The why now is because we have really
Avid Bioservices Inc (CDMO) Q1 2021 Earnings Call Transcript
Avid Bioservices Inc (NASDAQ: CDMO) Q1 2021 earnings call dated Sep. 08, 2021. Corporate Participants: Tim Brons -- Avid's Investor Relations Group Nicholas
IPO Alert: COVID-19 test maker Cue Health is all set to go public
Just eight months into the year, IPO activity has already reached all-time highs, with tech firms and biotechnology startups leading the rally.
Moderna (MRNA): Here are a few points to note while considering this stock
Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% on Monday. The stock has gained 291% since the beginning of the year